Primary care: Primary care for survivors of breast cancer

New England Journal of Medicine

Volumn 343, Issue 15, 2000, Pages 1086-1094

  Burstein, H J ^a   Winer, E P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; ANTINEOPLASTIC AGENT;

AMENORRHEA; BREAST CANCER; CANCER RISK; CANCER SCREENING; FEMALE; GENETIC PREDISPOSITION; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; BREAST TUMOR; CARDIOVASCULAR DISEASE; DRUG CONTRAINDICATION; FEMALE INFERTILITY; HORMONE SUBSTITUTION; MENOPAUSE; PRIMARY HEALTH CARE; PSYCHOLOGICAL ASPECT; RADIOTHERAPY; RISK FACTOR; SECOND CANCER; SURVIVOR; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INFERTILITY, FEMALE; MENOPAUSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; OSTEOPOROSIS; PRIMARY HEALTH CARE; RADIOTHERAPY; RISK FACTORS; SURVIVORS;

EID: 0034641832     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200010123431506     Document Type: Review

References (113)

1. Cancer prevalence and survivorship issues: Analyses of the 1992 national health interview survey
2. Annual hazard rates of recurrence for breast cancer after primary therapy
3. Symptomatology as an indicator of recurrent or metastatic breast cancer
4. A retrospective study of earliest indicators of recurrence in patients on eastern cooperative oncology group adjuvant chemotherapy trials for breast cancer: A preliminary report
5. A minimalist policy for breast cancer surveillance
6. Influence of early diagnosis on prognosis of recurrent breast cancer
7. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: A multicenter randomized controlled trial
8. Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial
9. Clinical practice guidelines for the use of tumor makers in breast colorectal cancer
10. Evolving perspectives in contralateral breast cancer
11. The genetic epidemiology of second primary breast cancer
12. Cancer in the contralateral breast after radiotherapy for breast cancer
13. The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer
14. Results of breast conserving therapy for early breast cancer and the role of mammographic follow-up
15. Recommended breast cancer surveillance guidelines
16. Assessing the risk of breast cancer
17. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2
18. Perceptions of follow-up care in women with breast cancer
19. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 and BRCA2 mutations
20. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
21. Complications of axillary lymph node dissection for carcinoma of the breast: A report based on a patient survey
22. Physical and psychological morbidity after axillary lymph node dissection for breast cancer
23. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer
24. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
25. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries
26. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy
27. Oncological aspects of immediate breast reconstruction following mastectomy for malignancy
28. Recurrent breast cancer following immediate reconstruction with myocutaneous flaps
29. Breast reconstruction in women treated with radiation therapy for breast cancer: Cosmesis, complications, and tumor control
30. Reconstruction and the radiated breast: Is there a role for implants?
31. Lymphedema
32. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy
33. Arm lymphedema in patients treated conservatively for breast cancer: Relationship to patient age and axillary node dissection technique
34. Conservative treatment of postmastectomy lymphedema: A controlled, randomized trial
35. Precipitating factors in lymphedema: Myths and realities
36. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer
37. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M. D. Anderson Hospital and Tumor Institute
38. Anthracycline-induced cardiotoxicity
39. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer
40. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience
41. Risk of menopause during the first year after breast cancer diagnosis
42. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer
43. Ovarian toxicity of breast cancer chemotherapy
44. Menstrual disruption in premenopausal breast cancer patients receiving CMF (IV) vs AC adjuvant chemotherapy
45. Early menopause in long-term survivors of cancer during adolescence
46. Tamoxifen in the treatment of breast cancer
47. Symptoms associated with tamoxifen treatment in postmenopausal women
48. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the national surgical adjuvant breast and bowel project P-1 study
49. Effect of tamoxifen on sexual functioning in patients with breast cancer
50. Variation in endometrial thickening in women with amenorrhea on tamoxifen
51. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer
52. Tamoxifen therapy for breast cancer and endometrial cancer risk
53. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
54. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
55. Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer
56. Surveillance for endometrial cancer in women receiving tamoxifen
57. Childbearing issues in breast carcinoma survivors
58. Pregnancy after breast cancer: From psychosocial issues through conception
59. Should women be advised against pregnancy after breast-cancer treatment?
60. Pregnancy after breast carcinoma: Outcomes and influence on mortality
61. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients
62. Pregnancy outcome in cancer patients: Experience in a large cooperative group
63. Pregnancy and lactation after breast-conserving therapy for early-stage breast cancer
64. Lactation after conservative breast surgery combined with radiation therapy
65. Risk of cancer after use of fertility drugs with in-vitro fertilisation
66. Cancer in women with infertility
67. Estrogen replacement therapy in breast cancer survivors: A time for change
68. Treatment of estrogen deficiency symptoms in women surviving breast cancer
69. Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed prospectively
70. Patient-specific decisions about hormone replacement therapy in postmenopausal women
71. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer
72. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography
73. Hormone replacement therapy and accuracy of mammographic screening
74. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy
75. Estrogen replacement therapy after treatment for localized breast carcinoma: Patient responses and opinion
76. Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer
77. Hormone replacement after breast cancer
78. Bone mineral density and risk of breast cancer in older women: The study of osteoporotic fractures
79. Bone mass and the risk of breast cancer among postmenopausal women
80. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients
81. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer
82. Treatment of postmenopausal osteoporosis
83. No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques
84. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomised trials
85. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes
86. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer
87. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
88. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
89. Hot flashes in postmenopausal women treated for breast carcinoma: Prevalence, severity, correlates, management, and relation to quality of life
90. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors
91. Megestrol acetate for the prevention of hot flashes
92. Preliminary data from a randomized evaluation of fluoxetine (Prozac) for treating hot flashes in breast cancer survivors
93. Venlafaxine alleviates hot flashes: An NCCTG trial
94. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes
95. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A north central cancer treatment group trial
96. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer
97. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy
98. Breast cancer survivors: Psychosocial concerns and quality of life
99. Psychological distress after initial treatment of breast cancer: Assessment of potential risk factors
100. Characteristics of women at risk for psychosocial distress in the year after breast cancer
101. Use of alternative medicine by women with early-stage breast cancer
102. Long-term quality of life after breast cancer: Comparison of 8-year survivors with population controls
103. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning
104. Dual effects of weight and weight gain on breast cancer risk
105. Physical activity and the risk of breast cancer
106. Alcohol and breast cancer in women: A pooled analysis of cohort studies
107. Dietary factors and the survival of women with breast carcinoma
108. Why women gain weight with adjuvant chemotherapy for breast cancer
109. Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis
110. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer
111. The effect of aerobic exercise on self-esteem and depressive and anxiety symptoms among breast cancer survivors
112. The effect of comorbidity on 3-year survival of women with primary breast cancer